Last Week’s Hot Topic on Pulmonary Fibrosis



Last week’s hot topic on pulmonary fibrosis was Experimental Pulmonary Fibrosis Therapy, GR-MD-02, Granted U.S. Patent Allowance and was written by Carolina Henriques.

This article is focused on Galectin Therapeutics, Inc‘s, announcement that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for its patent application “Method for Treatment of Pulmonary Fibrosis” — number 13/999,389 — on its lead compound GR-MD-02.

PF is a scarring of the lung tissue, which can seriously affect a patient’s breathing capability. In PF, scar tissue builds up in the walls of the air sacs in the lungs, eventually compromising oxygen levels into the blood. Low oxygen levels, in turn, contribute to shortness of breath, particularly when walking or exercising.

Read the latest news on pulmonary fibrosis:

How useful was this post?

Click on a star to rate it!

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

We are sorry that this post was not useful for you!

Let us improve this post!

Tell us how we can improve this post?

Leave a Comment

Your email address will not be published. Required fields are marked *